TY - JOUR
T1 - Heterozygous PINK1 p.G411S increases risk of Parkinson's disease via a dominant-negative mechanism
AU - Puschmann, Andreas
AU - Fiesel, Fabienne C.
AU - Caulfield, Thomas R.
AU - Hudec, Roman
AU - Ando, Maya
AU - Truban, Dominika
AU - Hou, Xu
AU - Ogaki, Kotaro
AU - Heckman, Michael G.
AU - James, Elle D.
AU - Swanberg, Maria
AU - Jimenez-Ferrer, Itzia
AU - Hansson, Oskar
AU - Opala, Grzegorz
AU - Siuda, Joanna
AU - Boczarska-Jedynak, Magdalena
AU - Friedman, Andrzej
AU - Koziorowski, Dariusz
AU - Rudzińska-Bar, Monika
AU - Aasly, Jan O.
AU - Lynch, Timothy
AU - Mellick, George D.
AU - Mohan, Megha
AU - Silburn, Peter A.
AU - Sanotsky, Yanosh
AU - Vilariño-Güell, Carles
AU - Farrer, Matthew J.
AU - Chen, Li
AU - Dawson, Valina L.
AU - Dawson, Ted M.
AU - Wszolek, Zbigniew K.
AU - Ross, Owen A.
AU - Springer, Wolfdieter
N1 - Funding Information:
A.P. is partially supported by the Swedish Parkinson Academy, The Swedish Parkinson Foundation (Parkinsonfonden), governmental funding for clinical research within the Swedish National Health Services (ALF), MultiPark, Lund University, Sweden, and Bundy Academy, Lund, Sweden. W.S. is partially supported by the National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS) [R01 #NS085070], the Michael J. Fox Foundation for Parkinson’s Research and the Foundation for Mitochondrial Medicine, the Mayo Clinic Center for Regenerative Medicine (CRM), Center for Individualized Medicine (CIM), and Center for Biomedical Discovery (CBD), the Marriott Family Foundation, and a Gerstner Family Career Development Award. F.C.F. is the recipient of a fellowship from the American Parkinson Disease Association (APDA). M.A. acknowledges support from the Uehara Memorial Foundation. Mayo Clinic Florida is a Morris K. Udall Parkinson’s Disease Research Center of Excellence [NIH/NINDS P50 #NS072187 to Z.K.W. and O.A.R.]. O.A.R. is supported by NIH/NINDS [R01 #NS078086]. Z.K.W. and O.A.R are supported by the Mayo Clinic Center for Individualized Medicine (CIM) and the Mayo Clinic Center for Regenerative Medicine (CRM). Z.K.W., O.A.R., and W.S. are recipients of Mayo Clinic Florida Neuroscience Focused Research Team Awards. O.H. is supported by European Research Council, Swedish Research Council, Swedish Brain Power and ALF. G.M. and M.F. acknowledge NHMRC project APP1084560. I.J-F. is supported by the CONCYT PhD program. M.S. is supported by MultiPark, Lund University, Sweden. The MultiPark sample collection was funded by MultiPark, Lund University, Sweden. V.L.D is supported by grants from the NIH/NINDS NS38377, MDSCRF 2007-MSCRFI-0420-00, 2009-MSCRFII-0125-00, MDSCRF 2012-MSCRFII-0268-00, MDSCRF 2013-MSCRFII-0105-00. T.M.D. is the Leonard and Madlyn Abramson Professor in Neurodegenerative Diseases, and is supported by grants from the NIH/NINDS NS38377, MDSCRF 2007-MSCRFI-0420-00, 2009-MSCRFII-0125-00, MDSCRF 2012-MSCRFII-0268-00, MDSCRF 2013-MSCRFII-0105-00, and the JPB Foundation. T.M.D. and V.L.D. acknowledge the joint participation by the Adrienne Helis Malvin Medical Research Foundation through their direct engagement in the continuous active conduct of medical research in conjunction with the Johns Hopkins Hospital and the Johns Hopkins University School of Medicine and the Foundation’s Parkinson’s Disease Program M-1.
Publisher Copyright:
© The Author (2016). Published by Oxford University Press on behalf of the Guarantors of Brain.
PY - 2017/1
Y1 - 2017/1
N2 - It has been postulated that heterozygous mutations in recessive Parkinson's genes may increase the risk of developing the disease. In particular, the PTEN-induced putative kinase 1 (PINK1) p.G411S (c.1231G4A, rs45478900) mutation has been reported in families with dominant inheritance patterns of Parkinson's disease, suggesting that it might confer a sizeable disease risk when present on only one allele. We examined families with PINK1 p.G411S and conducted a genetic association study with 2560 patients with Parkinson's disease and 2145 control subjects. Heterozygous PINK1 p.G411S mutations markedly increased Parkinson's disease risk (odds ratio = 2.92, P = 0.032); significance remained when supplementing with results from previous studies on 4437 additional subjects (odds ratio = 2.89, P = 0.027). We analysed primary human skin fibroblasts and induced neurons from heterozygous PINK1 p.G411S carriers compared to PINK1 p.Q456X heterozygotes and PINK1 wild-type controls under endogenous conditions. While cells from PINK1 p.Q456X heterozygotes showed reduced levels of PINK1 protein and decreased initial kinase activity upon mitochondrial damage, stress-response was largely unaffected over time, as expected for a recessive loss-of-function mutation. By contrast, PINK1 p.G411S heterozygotes showed no decrease of PINK1 protein levels but a sustained, significant reduction in kinase activity. Molecular modelling and dynamics simulations as well as multiple functional assays revealed that the p.G411S mutation interferes with ubiquitin phosphorylation by wild-type PINK1 in a heterodimeric complex. This impairs the protective functions of the PINK1/parkin-mediated mitochondrial quality control. Based on genetic and clinical evaluation as well as functional and structural characterization, we established p.G411S as a rare genetic risk factor with a relatively large effect size conferred by a partial dominant-negative function phenotype.
AB - It has been postulated that heterozygous mutations in recessive Parkinson's genes may increase the risk of developing the disease. In particular, the PTEN-induced putative kinase 1 (PINK1) p.G411S (c.1231G4A, rs45478900) mutation has been reported in families with dominant inheritance patterns of Parkinson's disease, suggesting that it might confer a sizeable disease risk when present on only one allele. We examined families with PINK1 p.G411S and conducted a genetic association study with 2560 patients with Parkinson's disease and 2145 control subjects. Heterozygous PINK1 p.G411S mutations markedly increased Parkinson's disease risk (odds ratio = 2.92, P = 0.032); significance remained when supplementing with results from previous studies on 4437 additional subjects (odds ratio = 2.89, P = 0.027). We analysed primary human skin fibroblasts and induced neurons from heterozygous PINK1 p.G411S carriers compared to PINK1 p.Q456X heterozygotes and PINK1 wild-type controls under endogenous conditions. While cells from PINK1 p.Q456X heterozygotes showed reduced levels of PINK1 protein and decreased initial kinase activity upon mitochondrial damage, stress-response was largely unaffected over time, as expected for a recessive loss-of-function mutation. By contrast, PINK1 p.G411S heterozygotes showed no decrease of PINK1 protein levels but a sustained, significant reduction in kinase activity. Molecular modelling and dynamics simulations as well as multiple functional assays revealed that the p.G411S mutation interferes with ubiquitin phosphorylation by wild-type PINK1 in a heterodimeric complex. This impairs the protective functions of the PINK1/parkin-mediated mitochondrial quality control. Based on genetic and clinical evaluation as well as functional and structural characterization, we established p.G411S as a rare genetic risk factor with a relatively large effect size conferred by a partial dominant-negative function phenotype.
KW - Heterozygous mutation
KW - Mitophagy
KW - PINK1
KW - Parkinson's disease
KW - Ubiquitin
UR - http://www.scopus.com/inward/record.url?scp=85018383742&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85018383742&partnerID=8YFLogxK
U2 - 10.1093/brain/aww261
DO - 10.1093/brain/aww261
M3 - Article
C2 - 27807026
AN - SCOPUS:85018383742
SN - 0006-8950
VL - 140
SP - 98
EP - 117
JO - Brain
JF - Brain
IS - 1
ER -